| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCITRANSLMED.3002461 |
| P698 | PubMed publication ID | 21697532 |
| P50 | author | Adrian V. S. Hill | Q22278197 |
| Helen McShane | Q58870907 | ||
| Richard Adebayo Adegbola | Q75114791 | ||
| Nicola Williams | Q87987961 | ||
| P2093 | author name string | Patrick K Owiafe | |
| Martin O C Ota | |||
| Sarah Rowland-Jones | |||
| Aderonke A Odutola | |||
| Simon Donkor | |||
| Olumuyiwa A Owolabi | |||
| Nathaniel J Brittain | |||
| P2860 | cites work | Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa | Q24647137 |
| A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection | Q28299361 | ||
| Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants | Q28303270 | ||
| Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa | Q28473318 | ||
| An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection | Q29616521 | ||
| Functional diversity of helper T lymphocytes | Q29619415 | ||
| Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | Q34361636 | ||
| Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis | Q34527217 | ||
| Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells | Q34605490 | ||
| Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis | Q37274874 | ||
| Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein | Q39571550 | ||
| Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants | Q40585476 | ||
| Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. | Q47384978 | ||
| T helper 2 biased de novo immune response to Keyhole Limpet Hemocyanin in humans. | Q51805215 | ||
| Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally | Q56461993 | ||
| P433 | issue | 88 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | The Gambia | Q1005 |
| randomized controlled trial | Q1436668 | ||
| tuberculosis | Q12204 | ||
| P304 | page(s) | 88ra56 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants | |
| P478 | volume | 3 |
| Q43519813 | A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants |
| Q35036289 | A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants |
| Q35889153 | A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults |
| Q38711772 | A review of clinical models for the evaluation of human TB vaccines |
| Q27315911 | Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis |
| Q37530299 | Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines |
| Q38848196 | Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. |
| Q37956378 | Do new TB vaccines have a place in the Expanded Program on Immunization? |
| Q40914004 | From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology |
| Q33624576 | Human genetics of tuberculosis: a long and winding road |
| Q38021238 | Human immune responses to vaccines in the first year of life: biological, socio-economic and ethical issues - a viewpoint. |
| Q34146613 | Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis |
| Q90466216 | Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial |
| Q36715923 | Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. |
| Q36641634 | Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns |
| Q64078255 | MVA85A vaccine to enhance BCG for preventing tuberculosis |
| Q94347757 | MVA85A vaccine to enhance BCG for preventing tuberculosis |
| Q94602401 | Malaria vaccines: facing unknowns |
| Q38194389 | Novel vaccine approaches for protection against intracellular pathogens. |
| Q35554825 | PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi |
| Q27024526 | Prime-boost approaches to tuberculosis vaccine development |
| Q35117812 | Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry |
| Q46796163 | Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial |
| Q29620144 | Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial |
| Q36888036 | Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. |
| Q53826203 | Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. |
| Q38011369 | Scaling up interventions to achieve global tuberculosis control: progress and new developments |
| Q33659150 | The next 10 years for tuberculosis vaccines: do we have the right plans in place? |
| Q36849770 | Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines |
| Q34806664 | Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.